The preclinical and clinical profile of dienogest. A short overview

Drugs of Today

Volumn 35, Issue SUPPL. C, 1999, Pages 3-12

  Oettel, Michael ^a   Graser T ^a   Hoffmann, H ^a   Moore, C ^a   Zimmermann, H ^a   Zimmermann, T ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DANAZOL; DIENOGEST; DIENOGEST PLUS ETHINYLESTRADIOL; DYDROGESTERONE; ESTRADIOL; ESTRADIOL VALERATE; ETHINYLESTRADIOL; GESTAGEN; GONADORELIN AGONIST; KLIMODIEN; LEUPRORELIN; LYNESTRENOL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; TRIPTORELIN; UNCLASSIFIED DRUG;

ACNE; BONE ATROPHY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG HALF LIFE; ENDOMETRIOSIS; HORMONE SUBSTITUTION; HUMAN; NONHUMAN; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; REVIEW; UTERUS BLEEDING;

EID: 0344417223     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Davenport-Hines, R. On the pill: A social history of oral contraceptives 1950-1970. Nature 1988, 396: 38.
2. Mishell, D. Oral contraception: Past, present, and future perspectives. Int J Fertil 1992, 37 (Suppl 1): 7-18.
3. Tayob, Y. Oral contraceptives: An epidemiological perspective. Int J Fertil 1992, 37 (Suppl 4): 199-203.
4. Hirvonen, E. Progestins. Maturitas 1996, 23 (Suppl): S13-S18.
5. Guengerich, F.P. Mechanism based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 1990, 3: 363-71.
6. Böcker, R., Kleingeist, B. Der Einfluß von Dienogest auf das humane Cytochrom P-450-Enzymsystem in vitro. In: Dienogest. Präklinik und Klinik eines Gestagens. Teichmann, A.T. (Ed.), W. de Gruyter: Berlin 2. Auflage 1995, 141-7.
7. Oettel, M., Holz, C. Hybrid progestins -the example of dienogest. In: Progestins and Antiprogestins in Clinical Practice. Sitruc-Ware, R., Mishell, D. (Eds.). Marcel Dekker Inc.: New York 1999 (in press).
8. Oettel, M., Bervoas-Martin, S., Elger, W. et al. A norprogestin without 17α-ethinyl group I: Dienogest from a pharmacokinetic point of view. Drugs of Today 1995, 31: 499-516.
9. Oettel, M., Carol, W., Elger, W. et al. A 19-norprogestin without 17α-ethinyl group II: Dienogest from a pharmacodynamic point of view. Drugs of Today 1995, 31: 517-36.
10. Oettel, M., Breitbarth, H., Elger, W. et al. The pharmacological profile of dienogest. Eur J Contraception Reprod Health Care 1998, 3: 1-12.
11. Foster R.H., Wilde, M.I. Dienogest. Drugs 1998, 56: 825-33.
12. Oettel, M., Carol, W., Gräser, T. et al. Der Einfluß einer Ethinylestradiol-Dienogest-Kombination auf die Serum-Androgen-Konzentrationen. Zentralbl Gynäkol 1997, 119: 597-606.
13. Gräser, T., Oettel, M. Organ targeting with the oral progestin dienogest. Drugs of Today 1996, 32 (Suppl. H): 43-55.
14. Schubert, K., Hobe, G., Kaufmann, G. et al. Studies on biotransformation of STS 557. Exper Clin Endocrinol 1983, 81: 168-74.
15. Hörhold-Schubert, C., Hobe, G., Kaufmann, G., Schumann, G. Zur Biotransformation von Dienogest durch Mikroorganismen. In: Dienogest. Präklinik und Klinik eines Gestagens. Teichmann, A.T. (Ed.). W. de Gruyter: Berlin 2. Auflage 1995, 51-8.
16. Oettel, M., Kaufmann, G., Kurischko, A. Das endokrinologische Profil von Metaboliten des Gestagens Dienogest. Pharmazie 1993, 48: 541-5.
17. Kuhnz, W., Gieschen, H. Predicting the oral bioavailibility of 19-nbortestosterone progestins in vivo from their metabolic stability in human liver microsomal preparations in vitro. Drug Metab Dispos 1998, 26: 1120-27.
18. Hoffmann, A., Reimann, I.R., Nassr, N., Hobe, G., Mellinger, U., Kuhl, H. Pharmakokinetik von Dienogest als Monopräparat und in Kombination mit Ethinylestradiol. In: Dienogest. Präklinik und Klinik eines Gestagens. Teichmann, A.T. (Ed.). W. de Gruyter: Berlin 2. Auflage 1995, 95-104.
19. Juchem, M., Schaffrath, M., Pollow, K., Hoffmann, G., Kaufmann, G. Dienogest: Bindungsstudien an verschiedenen Rezeptor- und Serumproteinen. In: Dienogest. Präklinik und Klinik eines Gestagens. Teichmann, A.T. (Ed.). W. de Gruyter: Berlin 2. Auflage 1995, 119-33.
20. Hobe, G., Hillesheim, H.G., Küntzel, B., Klinger, G. Studies on non-protein bound dienogest in plasma of different species. Naunyn-Schmiedeberg's Arch Pharmacol Suppl 1993, 347: R44.
21. Hobe, G, Hillesheim, H.G., Schumann, W., Ritter, P., Claußen, C. Studies on pharmacokinetics of STS 557 in animal species and man. Exper Endocrinol 1983, 81: 158-67.
22. Balogh, A., Liewald, T., Liewald, S. et al. Zum Einfluß eines neuen Gestagens -Dienogest - und seiner Kombination mit Ethinylestradiol auf die Aktivität von Biotransformationsreaktionen. Zentralblatt Gynäkologie 1990, 112: 735-746
23. Oettel, M., Bocker, T., Güttner, T., Horn, M., Stölzner, W. Studie zur Entwicklung eines geeigneten Modells der Endometriosis externa bei Kaninchen und Ratten und die Effekte von Dienogest und Danazol. Fertilität 1992, 8: 131-5.
24. Katsuki, Y., Takano, Y., Futamura Y. et al. Effects of dienogest, a synthetic steroid, on experimental endometriosis in rats. Europ J Endocrinol 1998, 138: 216-26.
25. Kauppila, A. Reappraisal of progestins in endometriosis therapy. Europ J Endocrinol 1998, 138: 134-6.
26. Moore, C., Köhler, G., Müller, A. The treatment of endometriosis with dienogest. Drugs of Today 1999, 35 (Suppl. C): 41-52.
27. Katsuki, Y., Nobukata, H., Ishikawa, T., Hamada, Y., Sato, M., Shibutani, Y. Effects of dienogest (a synthetic steroid) on coagulation, fibrinolysis, and platelet aggregation in female monkeys. Toxicol Letters 1998, 98: 105-3.
28. Berard, H., Massad, L. Multicentre, Open-label, Randomized, Controlled Clinical Trial Comparing the Efficacy of Dienogest (at a Dosage of 1 mg × 2 Daily) versus Decapeptyl® 3.75 (1 i.m. Injection Every 4 Weeks) Over 16 Weeks after Coelio-surgery in 2 Parallel Groups of 52 Patients with Endometriosis. Jenapharm Company documentation 1998.
29. Shaw, R.W. Treatment of endometriosis. Lancet 1992, 340: 1267-71.
30. The Gestrinone Italian Study group. Gestrinone versus a gonadotropin-releasing hormone agonist for treatment of pelvic pain associated with endometriosis: A multicenter, randomized, double-blind study. Fertil Steril 1996, 66: 911-919.
31. Vercellini, P., Cortesi, I., Crosignani, P.G. Progestins for symptomatic endometriosis: A critical analysis of the evidence. Fertil Steril 1997, 68: 393-401.
32. Snaith, L. The treatment of endometriosis by oral progestogens. Proc R Soc Med 1968, 61: 358-60.
33. Johnston W.I.H. Dydrogesterone and endometriosis. Br J Obstet Gynaecol 1976, 83: 77-80.
34. Walker, S.M. The treatment of endometriosis with dydrogesterone. Br J Clin Pract 1982, 24(Suppl): 40-6.
35. Overton, C.E., Lindsay, P.C., Johal, B. et al. A randomized, double-blind, placebo-controlled study of luteal phase dydrogesterone (Duphaston) in women with minimal to mild endometriosis. Fertil Steril 1994, 62: 701-7.
36. Moghissi, K.S., Boyce, C.R. Management of endometriosis with oral medroxyprogesterone acetate. Obstet Gynecol 1976, 47: 265-7.
37. Luciano, A.A., Turksoy, R.N., Carleo, J. Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis. Obstet Gynecol 1988, 72: 323-7.
38. Müller, A., Christensen, B., Henkel, A., Moore C, Schindler A.E. Treatment of endometriosis with the novel progestin dienogest. VI. World Congr Endometriosis (June 30-July 4, 1998, Quebec City) poster No. 341.
39. Moore, C., Walter, F., Mellinger, U., Zahradnik, H.P. Multizentrische Studie zu kontrazeptiver Sicherheit, Zyklusbeeinflussung und Verträglichkeit von MP2000 Mikropille-Ein Zwischenbericht. In: Dienogest. Präklinik und Klinik eines Gestagens. Teichmann, A.T. (Ed.). W. de Gruyter: Berlin 2. Auflage 1995, 203-212.
40. Moore, C., Feichtinger, W., Klinger, G. et al. Clinical findings with the dienogest-containing oral contraceptive Valette®. Drugs of Today 1999, 35 (Suppl. C): 53-68.
41. Zimmermann, T., Dietrich, H., Wisser, K.H., Hoffmann, H. Efficacy and tolerability of the dienogest-containing oral contraceptive Valette®. Results of a postmarketing surveillance study. Drugs of Today 1999, 35 (Suppl. C): 79-87.
42. Moore, C., Luderschmidt, C., Moltz, L., Oettel, M., Schreiber, G. Antiandrogenic properties of the dienogest-containing oral contraceptive Valette®. Drugs of Today 1999, 35 (Suppl. C): 69-78.
43. Zimmermann, T., Wisser, K.H., Dietrich, H. Effects of the dienogest-containing oral contraceptive Valette® on skin and hair. Results of a postmarketing study. Drugs of Today 1999, 35 (Suppl. C): 97-104.
44. Meade, T.W. Risks and mechanisms of cardiovascular events in users of oral contraceptives. Am J Obstet Gynecol 1988, 158: 1646-52.
45. Spitzer, W.O. Balanced view of risks of oral contraceptives. Lancet 1997, 350: 1566-7.
46. Burkman, R. The estrogen component of OCs: cardiovascular benefits and risks. Int J Fertil 1997, 42 (Suppl 1): 145-57.
47. Wenzl, R., Coelingk Bennink, H., van Beek, A., Spona, J., Huber, J. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17β-estradiol. Fertil Steril 1993, 60: 616-9.
48. Hirvonen, E., Allonen, H., Antilla, M. et al. Oral contraceptive containing natural estradiol for premenopausal women. Maturitas 1995, 21: 27-32.
49. Kivinen, S., Saure, A. Efficacy and tolerability of a combined oral contraceptive containing 17β-estradiol and desogestrel. Eur J Contracept Reprod Health Care 1996, 1: 183.
50. Kovacs, L., Hoffmann, H. A new low-dose oral contraception containing ethinylestradiol, estradiol and dienogest: First experience of its clinical use. In: Extragenital Effects of Oral Contraceptives. Elstein, M. (Ed.) The Parthenon Publishing Group: Carnforth 1997, 39-44.
51. Hoffmann, H., Moore, C., Zimmermann, H. et al. Approaches to the replacement of ethinylestradiol by natural 17β-estradiol in combined oral contraceptives. Exp Toxic Pathol 1998, 50: 458-64.
52. Hoffmann, H., Moore, C., Kovacs, L. et al. Alternatives for the replacement of ethinylestradiol by natural 17β-estradiol in dienogest-containing oral contraceptives. Drugs of Today 1999, 35 (Suppl. C): 105-113.
53. Katsuki, Y., Shibutani, Y., Aoki, D., Nozawa, S. Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins. Cancer 1997, 79: 169-76.
54. Mück, A.O., Seeger, H., Korte, K., Lippert, T.H. Effect of estradiol on calcium influx in human umbilical cord endothelial cells. Med Sci Res 1994, 22: 19.
55. Gräser, T., Koytchev, R., Römer, T., Georgiev, D.B., Müller, A., Hoffmann, H., Oettel, M. Dienogest as a progestin for hormone replacement therapy. Drugs of Today 1999, 35 (Suppl. C): 115-126.
56. Mück, A.O. Effects of Estradiol and Dienogest on Potential Markers of Vascular Function in Postmenopausal Women. Jenapharm Company documentation 1998.
57. Löffler, H., Saletu, B., Gruber, D. et al. Lebensqualität bei Schlafstörungen im Rahmen eines postmenopausalen Syndroms. J Menopause 1998, 5(4): 20-8.